Home
Insights

Other announcement

BCRI expands mission and vision

SAN DIEGO, July 16, 2020 /PRNewswire/ -- The CureScience™ Institute, a non-profit organization, focused on the acceleration of curative therapies for unmet needs, announced today a strategic expansion of its vision and mission. The Institute's initial focus was on translational research in oncology and neurological disorders. Based on recent successes, the Board of Directors has decided to strategically expand the Institute's vision to leverage early diagnostics, regenerative medicine, and immunotherapy to enable a new generation of precision medicines.

The Institute is expanding research activities with a strategic focus on establishing transdisciplinary ThinkTanks to bring thought-provoking ideas to the forefront and to accelerate therapeutic and translational research by developing a collaborative ecosystem of academic, industry, and patient-centric stakeholders. The focus will be on exploring "out of the box" solutions to address the bottlenecks in clinical translation and unmet needs in the delivery of care. Crucially, the Institute will be the catalyst that is needed to establish feasibility and clinical implementation models of these new ideas.

In addition to autoimmune and neurological disorders, different disorders will be adopted to explore solutions through transdisciplinary approaches. Strategically the Board of Directors chose to adopt COVID-19 as the current disorder theme due to its global impact. "I am proud to be part of this initiative, where the focus is on developing therapies through transdisciplinary approaches. The two key pieces, 'ThinkTanks' and 'Disorder themes,' are unique to our approach in addressing unmet needs," said Dr. Shashaanka Ashili. Regardingclinical implementation models, the Institute will engage patients and focus on developing patient engagement models to support the "disorder themes."

As a core focus, the Institute will be working with startups and other corporate stakeholders. The goals of this initiative are to enable novel technologies to strengthen early diagnosis and build a pipeline of patient-centric therapeutic repositories. The Institute has already participated in enabling startups with a focus on establishing a pipeline of cancer therapeutics.

To accomplish its mission, the Institute has expanded its Board of Advisors recruiting international scientists, including Dr. Jocopo Annese, founder of The Brain Observatory. "The Institute's approach of rapidly redirecting resources and orchestrating ThinkTanks towards priority focus areas is novel and unique in biomedical research. As a member of the Advisory Board, I am looking forward to contributing to this important challenge," said Dr. Jacopo Annese

More information at www.CureScience.org

[https://www.prnewswire.com/news-releases/curescience-institute-expands-vision-and-advisory-board-to-accelerate-innovation-301095253.html]

More announcements from CureScience

Funding announcement

CureScience announces patient centric support through Cureosyti program

Grant Opportunities $2,500-$25,000 CureScienceTM Institute is engaged in patient-centric research and development towards the discovery, development and production of novel medicines in a variety of therapeutic areas including but not limited to oncology, immunology and regenerative medicine. CureScienceTM, a 501(c)(3) nonprofit organization, focuses on research and development, patient development and the long term goal of providing quality health care products. CureScienceTM establishes and funds its own programs and also provides grants for other 501(c)(3) organizations engaged in patient care. CureScienceTM is seeking innovative patient engagement proposals that address patient care, patient support and/or patient education. Funding Amounts: Grants will be awarded in the amounts of $2,500-$25,000. The maximum funding amount for each patient engagement grant is up to $25,000. Grant information and applications available at [https://www.curescience.org/grants]

Team announcement

Dr. Boris Reznik of Biorasi and Venvalo Group joins CureScience as Advisor

Dr. Boris Reznik of Biorasi and Venvalo Group joins CureScience as Advisor

CureScienceTM Institute, a San Diego-based 501(c)(3) non-profit organization dedicated to accelerating novel curative therapies, announced today that Dr. Boris Reznik, has joined the organization's Advisory Board. Dr. Reznik is a veteran of multiple startups and has a strong track record of building companies across a diverse set of technologies-based industries with biomedical sciences being one of his primary focuses. Boris Reznik is the Chairman of Venvalo Group, venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems – a unique perspective in the drug and device development world. As the Chairman of Biorasi, a global CRO, he led development of novel therapeutics, from filing IND to getting approved NDA, for companies ranging from startups to Big Pharma. "I am delighted to welcome Dr. Reznik to our Advisory Board," said Dr. Shashaanka Ashili, CEO of CureScienceTM Institute. "He brings a unique experience in accelerating drug and device development for life sciences companies. We at CureScienceTM look forward to benefiting from Dr. Reznik's counsel as we work towards developing personalized therapeutic approaches." "CureScienceTM is a nonprofit institute with a strong team of professionals and an agile approach to novel therapeutics development," said Dr. Reznik. "I am impressed by CureScienceTM 's unconventional methodologies to improving patients' lives. With the rapidly changing life sciences industry, partnerships and collaborations are key to advancing science and I look forward to working with the CureScienceTM team on this front." "Dr. Reznik's experience in novel therapeutics development will be valuable to the researchers at CureScienceTM as we navigate the complex world of translating innovations and discoveries into clinical applications," said Dr. Tom Ichim, Director, Clinical Sciences at CureScienceTM. The Institute is committed to developing a preemptive and personalized approaches based on the early diagnosis, immunology, and regenerative medicine. To this end, CureScienceTM is focused on accelerating research and development programs internally and through the establishment of strategic partnerships with academic and industry partners. More information on CureScience at [www.CureScience.org] More information on Boris Reznik at [www.venvalo.com] [https://www.prnewswire.com/news-releases/curescience-institute-names-dr-boris-reznik-as-advisory-board-member-301233633.html]

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.